Headquartered in Alameda, CA Fiscal year ends December NASDAQ: EXEL exelixis.com
Exelixis is an oncology company that discovers, develops and commercializes small-molecule and biotherapeutic cancer medicines. Its revenue comes mainly from U.S. sales of the cabozantinib franchise: CABOMETYX, its flagship product, and COMETRIQ. It also earns collaboration revenues, chiefly royalties on cabozantinib sales outside the U.S. by partners Ipsen and Takeda, plus milestone and development reimbursement revenues. Its lead pipeline asset is zanzalintinib, a novel oral kinase inhibitor. Zanzalintinib is under FDA review, in combination with atezolizumab, for previously treated metastatic colorectal cancer (PDUFA date March 3, 2027). It is also in pivotal and earlier-stage trials across:
- colorectal cancer
- neuroendocrine tumors
- non-clear cell and clear cell renal cell carcinoma, including collaborations with Merck combining it with WELIREG
- bladder cancer
- prostate cancer
- squamous non-small cell lung cancer
- meningioma
Cabozantinib patent protection has been upheld against MSN. Settlement agreements set generic entry at January 1, 2031 and Azurity's 505(b)(2) product entry at December 1, 2030. The company returns capital through ongoing stock repurchase programs. Updated
CABOMETYX pulled in $603.2 million in U.S. net product revenue, topping expectations on both lines and keeping full-year revenue guidance intact. A lower tax-rate outlook adds margin cushion ahead of zanzalintinib's PDUFA date.
Pre-Market Stock Futures: Futures are trading higher this morning, after all the big funds and portfolio managers may have shown their hands on Wednesday, as the tech and chip stocks sell-off resumed…
When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles. With the S&P 500 trading at…
Alex Sirois In the past week, insiders returned to scoop up more shares of a fracking services company and a recreational boat maker.
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
Friday's top analyst upgrades and downgrades included Datadog, DexCom, Exelixis, Lam Research, Las Vegas Sands, Lyft, Match, Nasdaq, Next Era Energy, Norfolk Southern, Pfizer, Walmart and Wolfspeed.
Thursday's top analyst upgrades and downgrades included AT&T, Alibaba, Ally Financial, BioMarin Pharmaceutical, Box, Citrix Systems, Nio, Schlumberger and TJX Companies.
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
Thursday's top analyst upgrades and downgrades included Adobe, Baker Hughes, Best Buy, Cisco Systems, CyberArk Software, Enphase Energy, Grubhub, Jumia Technologies, SmileDirectClub, Under Armour and Wayfair.
Exelixis stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb, announced positive late-stage results from its kidney cancer study.
The top analyst upgrades, downgrades and initiations seen on Monday included Chipotle Mexican Grill, Delphi Technologies, Dollar General, Facebook, Ingersoll-Rand, Nike, Okta and Quest Diagnostics.
The top analyst upgrades, downgrades and initiations seen on Friday included Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, United Technologies and Zillow.
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
Sears, Weyerhaeuser, Laredo Petroleum, and Exelixis were among the stocks posting new 52-week lows Monday.
Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Chris Lange Exelixis is an oncology company that discovers, develops and commercializes small-molecule and biotherapeutic cancer medicines. Its revenue comes mainly from U.S. sales of the cabozantinib franchise: CABOMETYX, its flagship product, and COMETRIQ.
24/7 Wall St.'s 12-month price target for EXEL is $80.60, rated Buy. The Wall Street consensus target is $59.79. EXEL price prediction →
